SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 1999; 86: 2436-2446.
  • 2
    American Joint Committee on Cancer (AJC). Prostate. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010: 457-468.
  • 3
    Karadeniz T, Topsakal M, Aydogmus A, Beksan M. Role of RigiScan in the etiologic differential diagnosis of erectile dysfunction. Urol Int. 1997; 59: 41-45.
  • 4
    Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer. 1997; 79: 2154-2161.
  • 5
    Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate-specific antigen era. Cancer. 1997; 79: 1370-1380.
  • 6
    Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000; 46: 823-832.
  • 7
    Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000; 47: 609-615.
  • 8
    Greene FL. Prostate. In: Greene FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual, 6th ed. Philadelphia, PA: Lippincott Raven; 2002: 309-316.
  • 9
    Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004; 64: 1171-1176.
  • 10
    Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with 3-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001; 92: 1281-1287.
  • 11
    Price RA, Murphy S, McNeeley SW, et al. A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate. Int J Radiat Oncol Biol Phys. 2003; 57: 843-852.
  • 12
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995; 57: 289-300.
  • 13
    Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
  • 14
    Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2011; 92: 965-970.
  • 15
    R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
  • 16
    D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
  • 17
    Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166: 876-881.
  • 18
    Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following 3-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003; 21: 4568-4571.
  • 19
    Movsas B, Hanlon AL, Teshima T, Hanks GE. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997; 80: 1093-1102.
  • 20
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277: 1445-1451.
  • 21
    Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 1997; 79: 337-344.
  • 22
    Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994; 28: 33-37.
  • 23
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277: 1452-1455.
  • 24
    Makarov DV, Humphreys EB, Mangold LA, et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/mL. J Urol. 2006; 176: 554-558.
  • 25
    Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006; 175: 547-551.
  • 26
    Epstein JI. An update of the Gleason grading system. J Urol. 2010; 183: 433-440.
  • 27
    Jani AB, Vaida F, Hanks G, et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001; 96: 363-371.
  • 28
    Huang J, Vicini FA, Williams SG, et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? [Published online ahead of print November 16, 2011.] Int J Radiat Oncol Biol Phys. 2011.
  • 29
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004; 171: 1492-1499.
  • 30
    D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004; 22: 3726-3732.
  • 31
    D'Ambrosio DJ, Hanlon AL, Al-Saleem T, et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1082-1087.
  • 32
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351: 125-135.
  • 33
    D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005; 294: 440-447.
  • 34
    Vogel L. New US centre to boost comparative health research [serial online]. CMAJ. 2010; 182: E457-E58.
  • 35
    Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD. Observational methods in comparative effectiveness research [serial online]. Am J Med. 2010; 123( 12A): e16-e23.
  • 36
    Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics. 2010; 28: 905-913.
  • 37
    Shen X, Zaorsky NG, Mishra MV, et al. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncol. 2012; 8: 37-54.
  • 38
    Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02. Clin Cancer Res. 2007; 13: 3585-3590.
  • 39
    Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer. 2003; 97: 1630-1638.
  • 40
    Pollack A, DeSilvio M, Khor L, et al. Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92-02. Int J Radiat Oncol Biol Phys. 2003; 57( 2 suppl): S200-S201.
  • 41
    Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer. 2004; 110: 800-806.
  • 42
    Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999; 161: 1238-1243.
  • 43
    Pan Y, Zhang JS, Gazi MH, Young CY. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2003; 12: 769-774.
  • 44
    Di Lorenzo G, De Placido S, Autorino R, et al. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis. 2005; 8: 54-59.
  • 45
    Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005; 104: 962-967.
  • 46
    Bantis A, Giannopoulos A, Gonidi M, et al. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology. 2004; 15: 25-31.
  • 47
    Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 2002; 26: 312-319.
  • 48
    Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009; 55: 559-567.
  • 49
    Li X, Strauss L, Makela S, et al. Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor. Am J Pathol. 2004; 164: 1039-1048.